More Processed Foods, More Cardiovascular Problems medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce .
Amarin Corporation plcMarch 17, 2021 GMT
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk
Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups
Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction
REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021
March 17, 2021
Over the last year, an abundance of clinical research has been undertaken to understand common pathologies of COVID-19 illness, including the high rates of thrombosis and endothelial injury. A new state-of-the-art review notes that while an optimal antithrombotic therapy has yet to be determined and appears to be debatable, the ongoing studies provide needed clues and hope for improving outcomes.
“There is so much heterogeneity in protocols that hospitals are using for their ward patients, for their critically ill patients, and even for outpatients,” said senior author Behnood Bikdeli, MD (Brigham and Women’s Hospital, Boston, MA, and Yale University School of Medicine, New Haven, CT). “Then you have all these studies, with people feeling so strongly about one particular regimen versus the other. We thought: enough is enough. Let s systematically look to see what s out there.”
Share:
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk
Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups
Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction
REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., March 17, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT® STROKE at the International Stroke Conference 2021, being held virtually from March 17 – March 19, 2021,
ApoB May Better Predict Mortality Risk in Statin-Treated Patients medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.